↓ Skip to main content

Diagnosis and Treatment of Agoraphobia with Panic Disorder

Overview of attention for article published in CNS Drugs, August 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

patent
5 patents
wikipedia
17 Wikipedia pages

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
122 Mendeley
Title
Diagnosis and Treatment of Agoraphobia with Panic Disorder
Published in
CNS Drugs, August 2012
DOI 10.2165/00023210-200721090-00004
Pubmed ID
Authors

Giulio Perugi, Franco Frare, Cristina Toni

Abstract

Agoraphobia with panic disorder is a phobic-anxious syndrome where patients avoid situations or places in which they fear being embarrassed, or being unable to escape or get help if a panic attack occurs. During the last half-century, agoraphobia has been thought of as being closely linked to the recurring panic attack syndrome, so much so that in most cases it appears to be the typical development or complication of panic disorder. Despite the high prevalence of agoraphobia with panic disorder in patients in primary-care settings, the condition is frequently under-recognised and under-treated by medical providers. Antidepressants have been demonstrated to be effective in preventing panic attacks, and in improving anticipatory anxiety and avoidance behaviour. These drugs are also effective in the treatment of the frequently coexisting depressive symptomatology. Among antidepressant agents, SSRIs are generally well tolerated and effective for both anxious and depressive symptomatology, and these compounds should be considered the first choice for short-, medium- and long-term pharmacological treatment of agoraphobia with panic disorder. The few comparative studies conducted to date with various SSRIs reported no significant differences in terms of efficacy; however, the SSRIs that are less liable to produce withdrawal symptoms after abrupt discontinuation should be considered the treatments of first choice for long-term prophylaxis. Venlafaxine is not sufficiently studied in the long-term treatment of panic disorder, while TCAs may be considered as a second choice of treatment when patients do not seem to respond to or tolerate SSRIs. High-potency benzodiazepines have been shown to display a rapid onset of anti-anxiety effect, having beneficial effects during the first few days of treatment, and are therefore useful options for short-term treatment; however, these drugs are not first-choice medications in the medium and long term because of the frequent development of tolerance and dependence phenomena. Cognitive-behavioural therapy is the best studied non-pharmacological approach and can be applied to many patients, depending on its availability.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 2 2%
Australia 1 <1%
United Kingdom 1 <1%
Unknown 118 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 22 18%
Student > Bachelor 20 16%
Student > Doctoral Student 11 9%
Researcher 10 8%
Other 6 5%
Other 21 17%
Unknown 32 26%
Readers by discipline Count As %
Medicine and Dentistry 31 25%
Psychology 28 23%
Agricultural and Biological Sciences 8 7%
Nursing and Health Professions 5 4%
Biochemistry, Genetics and Molecular Biology 3 2%
Other 14 11%
Unknown 33 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 May 2022.
All research outputs
#5,446,629
of 25,374,647 outputs
Outputs from CNS Drugs
#512
of 1,388 outputs
Outputs of similar age
#38,817
of 187,950 outputs
Outputs of similar age from CNS Drugs
#164
of 541 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,388 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,950 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 541 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.